Certolizumab Pegol

Certolizumab pegol is a polyethylene-glycolated Fab' fragment of a humanized anti-TNF monoclonal antibody. Certolizumab pegol was evaluated in a phase 2, 12-week, double-blind, randomized, placebo-controlled, dose-response study in patients with moderate to severe CD (Schreiber et al. 2005). A total of 292 patients were randomized to receive subcutaneous cer-tolizumab 100,200, or 400 mg or placebo at Weeks 0,4, and 8. The primary endpoint was the percentage of patients with a clinical response (CDAI decrease of

> 100 or remission CDAI < 150) at Week 12. All certoli-zumab doses produced a significant clinical benefit over placebo by Week 2. The clinical response rates were highest for the 400-mg dose and were greatest at Week 10, although not significant at Week 12 (the primary endpoint). Among patients with elevated baseline C-reactive protein (CRP) levels, 53% of those treated with certolizumab 400 mg achieved clinical remission versus 18% of patients receiving placebo (p = 0.005). Adverse events were similar among groups.

In the PRECiSE 2, phase 3 study (Schreiber 2005), adult patients (N =668) with active CD who responded at Week 6 (CDAI decrease > 100 points from baseline) to open-label induction therapy with certolizumab 400 mg at Weeks 0,2, and 4, were randomized to maintenance therapy with certolizumab 400 mg or placebo every 4 weeks up to 24 weeks. Patients were stratified at baseline by CRP (<10 mg/l or > 10 mg/l) and by corti-costeroid and immunosuppressant use. The primary endpoint was the percentage of patients at Week 26 in the CRP > 10 mg/l stratum who maintained a clinical response after successful induction. Major secondary endpoints included remission (CDAI <150) in the CRP >10 mg/l stratum, and response and remission in the overall intention-to-treat (ITT) population. A total of 64% of patients responded to open-label induction therapy and were randomized. At Week 26, the clinical response rate (CDAI decrease > 100 points from baseline) in the CRP > 10 mg/l stratum was 62 % for certolizumab versus 34% for placebo (p <0.001). The clinical response rate at Week 26 in the overall ITT population was 63% for certolizumab versus 36% for placebo (p <0.001). Overall ITT population remission rates were 48% for certolizumab versus 29% for placebo (p <0.001). The most commonly reported adverse event was headache, which occurred with similar frequency among certolizumab and placebo groups. Results from the PRECiSE-1 phase 3 trial were recently presented. Similar to PRECiSE-2, certolizumab was more effective than placebo in achieving a clinical response among patients with CRP > 10 mg/l at baseline. Although there were trends toward greater efficacy in clinical remission results, differences between placebo and certolizumab did not achieve statistical significance in either the patients with CRP > 10 mg/l or among the overall ITT population (Sandborn et al. 2006). PRECiSE-3 and 4 are 24-month open-label trials to assess long-term safety that are currently ongoing.

Was this article helpful?

0 0
Stop Headache Drug Free

Stop Headache Drug Free

If you are suffering from headaches, you can make the pain stop just by following some basic but little known principles. Take 15 minutes browsing through this guide and you'll find dozens of tips to gain control in the battle against headache pain.

Get My Free Audio Book


Post a comment